Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

wh evans trading - chlorine present as sodium hypochlorite - pool algicide - swimming pool - algae

United Kingdom - English - myHealthbox

wockhardt uk ltd - amlodipine besilate - tablets - 5mg - calcium channel blockers – dihydropyridine derivatives - - essential hypertension - chronic stable and vasospastic anginal pectoris

United Kingdom - English - myHealthbox

wockhardt uk ltd - amlodipine besilate - tablets - 10mg - calcium channel blockers – dihydropyridine derivatives. - - essential hypertension - chronic stable and vasospastic anginal pectoris

European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v. - sugammadex - neuromuscular blockade - all other therapeutic products - reversal of neuromuscular blockade induced by rocuronium or vecuronium.for the peadiatric population: sugammadex is only recommended for routine reversal of rocuronium-induced blockade in children and adolescents.

European Union - English - EMA (European Medicines Agency)

merck sharp and dohme b.v - sitagliptin, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - for patients with type-2 diabetes mellitus:efficib is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.efficib is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.efficib is indicated as triple combination therapy with a ppar agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a ppar agonist.efficib is also indicated as add on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control.

European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertapenem sodium - community-acquired infections; streptococcal infections; staphylococcal infections; gram-negative bacterial infections; surgical wound infection; pneumonia, bacterial - antibacterials for systemic use, - treatmenttreatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required:intra-abdominal infections;community-acquired pneumonia;acute gynaecological infections;diabetic foot infections of the skin and soft tissue.preventioninvanz is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery.consideration should be given to official guidance on the appropriate use of antibacterial agents.

European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v. - sitagliptin, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - for patients with type 2 diabetes mellitus:janumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.janumet is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.janumet is indicated as triple combination therapy with a ppar  agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a ppar  agonist.janumet is also indicated as add on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control.

European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - measles virus enders’ edmonston strain (live, attenuated), mumps virus jeryl lynn (level b) strain (live, attenuated), rubella virus wistar ra 27/3 strain (live, attenuated) - rubella; mumps; immunization; measles - vaccines - m-m-rvaxpro is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months or older. for use in measles outbreaks, or for post-exposure vaccination, or for use in previously unvaccinated children older than 12 months who are in contact with susceptible pregnant women, and persons likely to be susceptible to mumps and rubella.,

European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v. - sitagliptin, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - for patients with type-2 diabetes mellitus:ristfor is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.ristfor is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.ristfor is indicated as triple combination therapy with a peroxisome proliferator-activated-receptor-gamma (pparγ) agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist.ristfor is also indicated as add-on to insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v. - sitagliptin, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - for patients with type-2 diabetes mellitus:velmetia is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.velmetia is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.velmetia is indicated as triple combination therapy with a ppar agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a ppar agonist.velmetia is also indicated as add on to insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control.